GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CV Sciences Inc (OTCPK:CVSI) » Definitions » ROC (Joel Greenblatt) %

CV Sciences (CV Sciences) ROC (Joel Greenblatt) %

: -244.99% (As of Dec. 2023)
View and export this data going back to 2011. Start your Free Trial

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. CV Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -244.99%.

The historical rank and industry rank for CV Sciences's ROC (Joel Greenblatt) % or its related term are showing as below:

CVSI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -533.46   Med: -106.48   Max: 293.96
Current: 168.66

During the past 13 years, CV Sciences's highest ROC (Joel Greenblatt) % was 293.96%. The lowest was -533.46%. And the median was -106.48%.

CVSI's ROC (Joel Greenblatt) % is ranked better than
97.18% of 1065 companies
in the Drug Manufacturers industry
Industry Median: 8.03 vs CVSI: 168.66

CV Sciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


CV Sciences ROC (Joel Greenblatt) % Historical Data

The historical data trend for CV Sciences's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CV Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -99.03 -148.62 -344.16 -533.46 293.96

CV Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -951.85 883.23 -138.66 -105.75 -244.99

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, CV Sciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CV Sciences ROC (Joel Greenblatt) % Distribution

For the Drug Manufacturers industry and Healthcare sector, CV Sciences's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where CV Sciences's ROC (Joel Greenblatt) % falls into.



CV Sciences ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.666 + 5.729 + 0.412) - (5.934 + 0 + 0)
=0.873

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.431 + 5.655 + 0.535) - (5.731 + 0 + 0)
=0.89

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of CV Sciences for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-3.556/( ( (0.594 + max(0.873, 0)) + (0.546 + max(0.89, 0)) )/ 2 )
=-3.556/( ( 1.467 + 1.436 )/ 2 )
=-3.556/1.4515
=-244.99 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CV Sciences  (OTCPK:CVSI) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


CV Sciences ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of CV Sciences's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


CV Sciences (CV Sciences) Business Description

Traded in Other Exchanges
N/A
Address
9530 Padgett Street, Suite 107, San Diego, CA, USA, 92126
CV Sciences Inc is a consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, which are sold through a range of sales channels from business-to-business (B2B) to business-to-consumer (B2C). The company also operates a drug development program focused on developing and commercializing cannabidiol (CBD)-based novel therapeutics.
Executives
William Mccorkle director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Corroon James Michael Jr. director 9530 PADGETT STREET, SUITE 107, SAN DIEGO CA 92126
Maroon Joseph C Md director 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Mona Michael Joseph Jr director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Paul Blake director 145 BRANDYWINE PKWY, WEST CHESTER PA 19380
Douglas Jesse Mackay officer: Sr VP Scientific/Regulatory 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Joseph D Dowling officer: Chief Financial Officer 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Joerg Grasser officer: CFO 2688 SOUTH RAINBOW BLVD STE B, LAS VEGAS NV 89146
Elizabeth Ann Altman director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Terri F Graham director C/O JACK IN THE BOX INC, 9330 BALVOA AVE, SAN DIEGO CA 92123
Stephen Martin Schmitz director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Gary Sligar director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
James A Mcnulty director C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Larry Phillip Raskin director 1630 FUNNY CIDE DRIVE, WAXHAW NC 28173
Mackay Ventures Inc. other: Member 10% holding group 6325 S. JONES BOULEVARD #500, LAS VEGAS NV 89118